+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets



Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets



Neuroscience 115(4): 1047-1058, 16 December



Chronic administration of L-DOPA to MPTP-treated common marmosets induces marked dyskinesia while repeated administration of equivalent antiparkisonian doses of ropinirole and bromocriptine produces only mild involuntary movements. The occurrence of dyskinesia has been associated with an altered balance between the direct and indirect striatal output pathways. Using in situ hybridisation histochemistry, we now compare the effects of these drug treatments on striatal preproenkephalin-A (PPE-A) and adenosine A(2a) receptor mRNA expression as markers of the indirect pathway and striatal preprotachykinin (PPT) mRNA and preproenkephalin-B (PPE-B, prodynorphin) mRNA expression as markers of the direct pathway.The equivalent marked losses of specific [3H]mazindol binding in the striatum of all drug treatment groups confirmed the identical nature of the nigral cell loss produced by MPTP treatment. MPTP-induced destruction of the nigro-striatal pathway markedly increased the level of PPE-A mRNA in the caudate nucleus and putamen and decreased the levels of PPT and PPE-B mRNA relative to normal animals. Repeated treatment with L-DOPA for 30 days produced marked dyskinesia but had no effect on the MPTP-induced increase in PPE-A mRNA in the caudate nucleus and putamen. In contrast, L-DOPA treatment normalised the MPTP-induced decrease in the level of PPT and PPE-B mRNA. Repeated treatment with ropinirole produced little or no dyskinesia but markedly reversed the MPTP-induced elevation in PPE-A mRNA in the caudate nucleus and putamen. However, it had no effect on the decrease in PPT or PPE-B mRNA. Similarly, bromocriptine treatment which induced only mild dyskinesia attenuated the MPTP-induced elevation in PPE-A mRNA in the caudate nucleus and putamen with no effect on reduced striatal PPT or PPE-B mRNA. Neither MPTP treatment nor treatment with L-DOPA, bromocriptine or ropinirole had any effect on adenosine A(2a) receptor mRNA in the striatum. These patterns of alteration in striatal PPE-A and PPT and PPE-B mRNA produced by L-DOPA, bromocriptine and ropinirole show differential involvement of markers of the direct and indirect striatal output pathways related to improvement of locomotor activity and mirror the relative abilities of the drugs to induce dyskinesia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010147403

Download citation: RISBibTeXText

PMID: 12453478

DOI: 10.1016/s0306-4522(02)00535-3


Related references

Differential effects of ropinirole, bromocriptine and L-Dopa on striatal preproenkephalin and preprotachykinin mRNA expression in MPTP-treated common marmosets. British Journal of Pharmacology 122(PROC Suppl. ): 161P, 1997

Effects of repeated treatment with combinations of L-DOPA and ropinirole on dyskinesia induction in MPTP-treated common marmosets. British Journal of Pharmacology 123(PROC Suppl. ): 252P, 1998

A comparison of ropinirole, L-dopa, and bromocriptine treatment on the development of dyskinesia in MPTP-treated common marmosets. Neurology 48(3 Suppl. 2): A119, 1997

Changes in striatal preproenkephalin A and preprotachykinin mRNA expression The effect of L-dopa, bromocriptine, and ropinirole in MPTP-treated marmosets. Neurology 50(4 Suppl. 4): A135, 1998

Ropinirole, bromocriptine and L-DOPA have a differential effect on striatal dopamine D-2 and D-3 but not D-1 receptor mRNA expression in MPTP-treated marmosets. British Journal of Pharmacology 136(Proceedings Suppl.): 68P, 2002

Differential effects of ropinirole, bromocriptine and L-DOPA on striatal dopamine D-2 receptor binding in MPTP-treated common marmosets. British Journal of Pharmacology 122(PROC Suppl. ): 315P, 1997

Effects of repeated treatment with L-DOPA, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets. British Journal of Pharmacology 118(PROC Suppl. JULY): 37P, 1996

Inducing dyskinesia in MPTP-treated common marmosets The effects of repeated treatment with combinations of L-dopa and ropinirole. Neurology 50(4 Suppl. 4): A135, 1998

Comparison of repeated treatment with L-DOPA, pergolide and apomorphine on dyskinesia induction in MPTP-treated common marmosets. British Journal of Pharmacology 125(PROC Suppl. ): 4P, 1998

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental Neurology 204(1): 162-170, 2007

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Movement Disorders 17(5): 887-901, 2002

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Movement Disorders 13(2): 234-241, 1998

L-DOPA, Ropinirole and Bromocriptine have a Differential Effect on Srtiatal Glutamic Acid Decarboxylase 65 and 67 mRNA Expression in MPTP-treated Marmosets. FASEB Journal 18(4-5): Abst 398 3, 2004

Differential effects of ropinirole, bromocriptine and L-DOPA on striatal preprodynorphin mRNA expression in the MPTP-treated marmoset. British Journal of Pharmacology 128(PROC Suppl. ): 282P, 1999